type-1 diabetes program (Anokion)

N/A

Report date: 2025/03/20 10:12:26
NME

Base Information

Drug Nametype-1 diabetes program (Anokion)
Drug Alias Nametype-1 diabetes program (Kanyos Bio)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKanyos Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnokion
Inactive CompaniesKanyos Bio Inc
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A